Effect of Ezetimibe Coadministered With Atorvastatin in 628 Patients With Primary Hypercholesterolemia: A Prospective, Randomized, Double-Blind Trial

By Christie M. Ballantyne, J. Houri, A. Notarbartolo, L. Melani, L. Lipka, R. Suresh, Steven Sun, A. Lebeaut, P. Sager, E. Veltri. Circulation, 2003

680 citations recorded by the source corpus.

Subfields: Cancer Research, Endocrinology, Diabetes and Metabolism, Surgery

View Paper: https://www.semanticscholar.org/paper/8677c25d528ed20e6731dc0c1380cc64e0804917

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. P. Ridker

In Endocrinology, Diabetes and Metabolism

1. K. ‐. Tseng
2. P. Ridker
3. Peter Libby

In Surgery

1. K. ‐. Tseng
2. P. Ridker
3. Peter Libby
4. L. Melvin

Citations in the corpus

• Standards of Medical Care in Diabetes–2006 (2006, background): “The combination of statins with other lipid-lowering drugs such as ezetimibe may allow achievement of the LDL goal with a lower dose of a statin in such patients (135), but no data are available as to whether such combination therapy is more effective than a statin alone in preventing cardiovascular”
• Anti-Inflammatory Effects of Statins: Clinical Evidence and Basic Mechanisms (2005, background): “The independence of CRP reduction from LDL reduction has recently been underscored in clinical studies of ezetimibe, a non-statin lipid lowering agent, which when given as a monotherapy significantly reduces LDL but has no effect on CR”